In-Depth Insights into the Poly ADP-Ribose Polymerase (PARP) Inhibitor Market: Growth, Trends, and Opportunities for 2025-2034
Get 20% off on Global Market Reports until March 31st! Use code FY25SAVE at checkout.
How has the poly adp-ribose polymerase (parp) inhibitor market grown in recent years?
The market for Poly ADP-ribose polymerase (PARP) inhibitors has seen a significant surge recently. Its size is projected to rise from $8.39 billion in 2024 to $9.41 billion in 2025, demonstrating a compound annual growth rate (CAGR) of 12.1%. The driving factors of this progression during the past years include clinical studies, regulatory accreditations, competitive market dynamics, drug amalgamations, and sustained patient advocacy.
How is the poly adp-ribose polymerase (parp) inhibitor market size expected to evolve during the forecast period?
The market size for the poly ADP-ribose polymerase (PARP) inhibitor is predicted to witness speedy expansion in the forthcoming years, as it is projected to reach $14.67 billion by 2029, with a compound annual growth rate (CAGR) of 11.7%. The rise during the anticipated period can be ascribed to factors such as extended indications, tailor-made medicine, the creation of biomarkers, health economy, and newly emerging markets. Predominant trends in the forecast duration encompass precision health, progression in immunotherapy, targeted treatments, the application of artificial intelligence in drug identification, and patient-focused healthcare.
Get your poly adp-ribose polymerase (parp) inhibitor market report here!
Which key drivers are propelling the poly adp-ribose polymerase (parp) inhibitor market’s growth?
The escalating prevalence of ovarian cancer is anticipated to drive the expansion of the poly ADP-ribose polymerase (PARP) inhibitor market onward. Ovarian cancer is a malignant tumor that forms in one or both of a woman’s ovaries, a critical component of the female reproductive system responsible for egg production and female hormone secretion. Factors contributing to the growth of ovarian cancer include genetic predisposition, an aging demographic, environmental factors, and hormonal imbalances. Poly ADP-Ribose Polymerase (PARP) Inhibitors are used for ovarian cancer treatment, targeting DNA repair mechanisms, specifically in patients carrying BRCA mutations, resulting in synthetic lethality and improved tumor cell death. For example, the World Ovarian Cancer Coalition, a non-profit organization based in Canada, projected in February 2024 that the annual death toll from ovarian cancer among women would rise to 350,956, up nearly 70% from 2022. Therefore, the escalating prevalence of ovarian cancer is fueling the expansion of the poly ADP-ribose polymerase (PARP) inhibitor market.
What are the market segments in the poly adp-ribose polymerase (parp) inhibitor industry?
The poly ADP-ribose polymerase (PARP) inhibitor market covered in this report is segmented –
1) By Drug Type: Talazoparib, Veliparib, Olaparib, Other Drug Types
2) By Distribution Channel: Hospital Pharmacy, Online Pharmacy, Retail Pharmacy, Other Distribution Channels
3) By Application: Ovarian Cancer, Breast Cancer, Other Applications
4) By End Users: Hospitals, Homecare, Specialty Clinics, Other End Users
Subsegments:
1) By Talazoparib: Talazoparib For Breast Cancer, Talazoparib For Ovarian Cancer, Talazoparib For Prostate Cancer, Talazoparib For Other Cancers
2) By Veliparib: Veliparib For Breast Cancer, Veliparib For Ovarian Cancer, Veliparib For Non-Small Cell Lung Cancer (Nsclc), Veliparib For Other Cancers
3) By Olaparib: Olaparib For Breast Cancer (Her2-negative), Olaparib For Ovarian Cancer (Brca-mutated), Olaparib For Prostate Cancer (Brca-Mutated), Olaparib For Pancreatic Cancer (Brca-Mutated), Olaparib For Other Cancers
4) By Other Drug Types: Niraparib, Rucaparib, Pembrolizumab (Combination Therapy With Parp Inhibitors), Other Parp Inhibitors (Emerging Drugs In Clinical Trials)
Get your free sample now – explore exclusive market insights:
https://www.thebusinessresearchcompany.com/sample.aspx?id=15637&type=smp
Which leading companies are shaping the growth of the poly adp-ribose polymerase (parp) inhibitor market?
Major companies operating in the Poly ADP-ribose polymerase (PARP) inhibitor market are Pfizer Inc., Johnson & Johnson Services Inc., AbbVie Inc., Bayer AG, Novartis AG, Sanofi S.A., AstraZeneca plc, GlaxoSmithKline plc., Takeda Pharmaceutical Company Limited, Merck KGaA, Teva Pharmaceutical Industries Ltd., Daiichi Sankyo Company Limited, Eisai Co. Ltd., Ipsen Biopharmaceuticals Inc., Genentech Inc., BioMarin Pharmaceutical Inc., Seattle Genetics Inc., Medivation Inc., Myriad Genetics Inc., PharmaMar S.A., Clovis Oncology, Nektar Therapeutics, Loxo Oncology Inc., Tolero Pharmaceuticals Inc., Everest Pharmaceuticals, Verastem Inc
What emerging trends are influencing the growth of the poly adp-ribose polymerase (parp) inhibitor market?
In a bid to provide customized treatment options for cancer patients with specific genetic mutations, prominent companies in the poly ADP-ribose polymerase (PARP) inhibitor market are working on the development of generic PARP inhibitors. Such inhibitors function by obstructing the activity of the enzyme poly ADP-ribose polymerase (PARP). As an illustration, Zydus Lifesciences Limited, a pharmaceutical company based in India, released a PARP inhibitor named Olaparib, under its brand IBYRA, in March 2024. IBYRA is designed to target specific genetic mutations present in various cancers such as breast, ovarian, prostate, and pancreatic. Its aim is to increase the accessibility of advanced cancer treatment. Particularly, the drug is effective for patients with HRD-positive or BRACA mutations as it aids in delaying the progression of the disease.
Unlock exclusive market insights – purchase your research report now for a swift delivery!
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=15637
Which geographic areas are influencing the growth of the poly adp-ribose polymerase (parp) inhibitor market?
North America was the largest region in the poly ADP-ribose polymerase (PARP) inhibitor market in 2023. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the Poly ADP-ribose polymerase (PARP) inhibitor market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Browse Through More Similar Reports By The Business Research Company:
Interleukin Inhibitors Global Market Report 2024
https://www.thebusinessresearchcompany.com/report/interleukin-inhibitor-global-market-report
PD-1 and PDL1 Inhibitors/ Immune Checkpoint Inhibitors Global Market Report 2024
HER2 Inhibitors Global Market Report 2024
https://www.thebusinessresearchcompany.com/report/her2-inhibitor-global-market-report
About The Business Research Company:
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.
Contact us at:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 3156230293
Asia +44 2071930708
Europe +44 2071930708
Email us at [email protected]
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
Found this article helpful? Share it on:
